Shares of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) experienced a substantial one-day gain of 65.6% following an agreement under which Servier will acquire the company for $21.50 in cash per share. The purchase price places Day One’s total equity value at roughly $2.5 billion.
The offer equates to a roughly 68% premium versus Day One’s closing price on Thursday and about an 86% premium over the one-month volume weighted average price as of Thursday. Servier will initiate a cash tender offer to purchase all issued and outstanding shares of Day One’s common stock under the terms of the merger agreement.
The parties anticipate the transaction will be completed in the second quarter of 2026, subject to customary closing conditions. Those conditions include the tender of at least a majority of Day One’s outstanding shares and clearance under U.S. antitrust regulations. If the tender offer is successful, Servier has stated it will acquire any remaining shares through a subsequent merger for the same per-share cash consideration.
Servier characterized the acquisition as a strategic move to position the company as a leader in pediatric low-grade glioma and to broaden its oncology portfolio with programs spanning from early-stage research through phase 3. Servier intends to fund the purchase from its existing cash and investment resources.
Day One’s Board of Directors has recommended that shareholders tender their shares in the offer. The board’s recommendation accompanies Servier’s public tender terms and the planned second-step merger if the initial offer secures the necessary level of participation.
Market reaction included analyst repositioning. Jones Trading analyst Soumit Roy downgraded Day One from Buy to Hold, setting a price target of $21.50, up from $20.00. Roy commented, "The M&A deal value is exactly inline with our expectation of $2.4-2.6BN, and fairly matches our current PT of $20/share."
The transaction and attendant market response will be watched closely by investors in biotech and pharmaceutical equities, particularly those focused on oncology pipeline value and deal-driven revaluations.
Summary
Servier will acquire Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at approximately $2.5 billion. The proposed transaction carries material premiums to recent trading levels, is expected to close in Q2 2026 pending customary conditions including a majority tender and U.S. antitrust clearance, and will be funded from Servier’s available cash and investments. Day One’s board recommends shareholders tender, and an analyst has adjusted coverage to reflect the deal value.